Advertisement

Breast Cancer
Supportive Care

Novel Selective Biomarker Tool May Help Select Effective Targeted Therapies in Patients With Metastatic Breast Cancer

A novel selective biomarker tool (Troplex) may help select which antibody-drug conjugate therapy could be most effective in patients with metastatic breast cancer, according to findings presented by Robbins et al at the 2023 San Antonio Breast Cancer Symposium (Abstract PO3-13-11).

Background

...

Breast Cancer
Supportive Care

Patients With HR-Positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence

Using fertility preservation and/or assisted reproductive technologies (ART) did not adversely impact 3-year cancer recurrence rates among patients with hormone receptor–positive breast cancer who paused endocrine therapy to become pregnant, according to results from the POSITIVE trial presented at ...

Breast Cancer

Novel Targeted Therapies May Benefit Patients With Metastatic Hormone Receptor–Positive/HER2-Negative Breast Cancer

Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patients with metastatic hormone receptor–positive/HER2-negative breast cancer. The data were shared in oral...

Breast Cancer

Younger Postmenopausal Patients With Early-Stage Breast Cancer May Be Able to Safely Omit Adjuvant Radiotherapy

Almost all postmenopausal patients aged 50 to 69 years with stage I hormone receptor–positive breast cancer and low scores on a common genetic test who opted out of adjuvant radiotherapy were disease-free 5 years after surgery, according to results from the IDEA clinical trial presented at the 2023 ...

Breast Cancer

Tucatinib Plus T-DM1 May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer

A combination of two HER2-targeted drugs—tucatinib and ado-trastuzumab emtansine (T-DM1), extended progression-free survival among patients with unresectable, locally advanced, or metastatic HER2-positive breast cancer compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial...

Breast Cancer

Neoadjuvant Chemotherapy May Help Some Patients With Breast Cancer Skip Regional Nodal Irradiation

For patients whose breast cancer converted from lymph node–positive to lymph node–negative disease after neoadjuvant chemotherapy, skipping adjuvant regional nodal irradiation did not increase the risk of disease recurrence or death 5 years after surgery, according to results from the NRG...

Breast Cancer

Combining Ribociclib With Hormone Therapy Improves Patient Outcomes in Early-Stage Breast Cancer: NATALEE

Targeted treatment with ribociclib plus hormone therapy provided significant invasive disease–free survival benefits in patients with early-stage hormone receptor–positive, HER2-negative breast cancer at risk of disease recurrence. Results from the phase III NATALEE trial, led by researchers at The ...

Breast Cancer

Recipients of 2023 Susan G. Komen Breast Cancer Awards Honored

Susan G. Komen presented its 2023 Breast Cancer Awards to four physician-scientists and one research advocate for their contributions to advancing breast cancer discoveries and improving patient outcomes. The five recipients were recognized at the Susan G. Komen Breast Cancer Awards event in San...

Breast Cancer

Abemaciclib Plus AI in Postmenopausal Patients With Advanced Breast Cancer: Final Overall Survival Analysis From MONARCH 3

Final overall survival results from the MONARCH 3 trial were reported in a late-breaking presentation during the 2023 San Antonio Breast Cancer Symposium (Abstract GS01-12). MONARCH 3 evaluated abemaciclib in combination with an aromatase inhibitor (AI) compared with an AI alone as initial...

Breast Cancer
Survivorship

Some Breast Cancer Survivors May Safely De-escalate Mammography 3 Years After Surgery

Women aged 50 or older who had less-frequent mammography 3 years after curative surgery for early-stage breast cancer had similar outcomes as women who had annual mammography, according to results from the Mammo-50 trial presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS03-02).

...

Breast Cancer

Skipping Adjuvant Radiotherapy May Not Impact Risk of Recurrence or Progression in Patients With Low-Risk DCIS

Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable 5-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the 2023 San...

Breast Cancer
Genomics/Genetics

Potentially Targetable Fusion RNAs May Be More Common in Metastatic Breast Cancer Than Previously Realized

Comprehensive profiling of fusion RNAs present in a large cohort of metastatic breast tumors revealed unique fusion mutations that may be therapeutically targetable, according to results presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS03-09).

Fusion mutations occur when a...

Breast Cancer
Genomics/Genetics

Genetic Characteristics of HER2-Low Advanced Breast Cancers May Guide Treatment Selection

Researchers have revealed significant differences in the genetic characteristics of HER2-low advanced breast cancers, which may lead to the development of novel therapeutics for patients, according to recent findings presented by Kahn et al at the 2023 San Antonio Breast Cancer Symposium (Abstract...

Breast Cancer
Supportive Care

Using Estrogen Levels to Predict Who May Benefit From Preventive Treatment With Anastrozole

Investigators have found that estrogen levels measured through blood tests may be predictive of which individuals at high risk of breast cancer will benefit from aromatase inhibitors, according to a recent study presented by Cuzick et al at the 2023 San Antonio Breast Cancer Symposium (Abstract...

Breast Cancer
Supportive Care

Exercise May Boost Quality of Life for Patients With Metastatic Breast Cancer

Patients with metastatic breast cancer who took part in a 9-month structured exercise program reported less fatigue and an improved quality of life compared to those who did not participate in the exercise program, according to results from the PREFERABLE-EFFECT trial presented at the 2023 San...

Breast Cancer
Issues in Oncology

Risk Model May Accurately Predict Aromatase Inhibitor Nonadherence

A novel risk model may be effective at using baseline sociodemographic and financial measures to predict the risk of long-term aromatase inhibitor nonadherence among patients with breast cancer, according to new findings presented by Hershman et al at the 2023 San Antonio Breast Cancer Symposium (

Head and Neck Cancer
Gastroesophageal Cancer
Issues in Oncology

Ultraprocessed Food May Heighten Risk of Head and Neck Cancer and Esophageal Adenocarcinoma

A higher consumption of ultraprocessed foods may be associated with the development of cancer of the upper–aerodigestive tract such as head and neck cancer and esophageal adenocarcinoma, according to a recent study published by Morales-Berstein et al in the European Journal of Nutrition. The new...

Breast Cancer

Study Finds Link Between T-Cell Diversity in Peripheral Blood, Patient Age, and Stage of Breast Cancer Development

A large cohort study of peripheral blood T-cell receptor (TCR) clonotype diversity in patients with breast cancer diagnosed with either ductal carcinoma in situ or de novo stage IV disease has found that the diversity of T cells is associated with age and intratumor immune status and might be...

Lymphoma

Mantle Cell Lymphoma: Predictive Value of Measurable Residual Disease With Rituximab Maintenance

In an analysis from the European Mantle Cell Lymphoma Elderly Trial reported in the Journal of Clinical Oncology, Hoster et al found that outcomes with rituximab maintenance were better in patients aged ≥ 60 years with mantle cell lymphoma who had measurable residual disease (MRD)-negative vs...

Bladder Cancer

Erdafitinib vs Chemotherapy in Previously Treated, FGFR-Mutated Advanced Urothelial Carcinoma

As reported in The New England Journal of Medicine by Yohann Loriot, MD, PhD, and colleagues, cohort 1 of the phase III THOR trial has shown improved overall survival with erdafitinib vs chemotherapy in patients with locally advanced, unresectable, or metastatic urothelial carcinoma with...

Lymphoma
Cost of Care
Issues in Oncology

CAR T-Cell Therapy May Be Effective—but Unaffordable—as Second-Line Therapy for Patients With DLBCL

Investigators have found that chimeric antigen receptor (CAR) T-cell therapy may be an effective but unaffordable second-line treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL), according to a recent study published by Kelkar et al in the Annals of Internal Medicine.

...

Gynecologic Cancers

Adding Durvalumab to Chemoradiotherapy in Locally Advanced Cervical Cancer

As reported in The Lancet Oncology by Bradley J. Monk, MD, and colleagues, the phase III CALLA trial showed no significant improvement in progression-free survival with the addition of durvalumab to chemoradiotherapy in previously untreated patients with locally advanced cervical cancer.

Study...

Hepatobiliary Cancer

First-Line Treatment of Advanced HCC: Addition of Pembrolizumab to Lenvatinib

As reported in The Lancet Oncology by Josep M. Llovet, MD, and colleagues, the phase III LEAP-002 trial has shown that the addition of pembrolizumab to lenvatinib in the first-line treatment of unresectable hepatocellular carcinoma did not reach statistical superiority thresholds for overall or...

CNS Cancers

Everolimus for Pediatric Recurrent/Progressive Low-Grade Glioma

In the phase II PNOC001 trial reported in the Journal of Clinical Oncology, Daphne A. Haas-Kogan, MD, MBA, and colleagues found that everolimus showed activity in pediatric patients with recurrent or progressive low-grade glioma. PI3K/AKT/mTOR pathway activation was not correlated with clinical...

Solid Tumors
Issues in Oncology

Chronic Health Conditions May Be Prevalent Among LGB Adolescent and Young Adult Cancer Survivors

Investigators have found that lesbian, gay, and bisexual (LGB) adolescent and young adult cancer survivors in the United States may be more likely to report chronic health conditions compared with their LGB peers without a cancer diagnosis and heterosexual counterparts with a history of cancer,

Lung Cancer
Issues in Oncology

Lung-MAP Trial Demonstrates Potential of Public-Private Partnerships in Advancement of Cancer Therapy

The unique public-private partnership that undergirded the Lung-MAP trial for almost a decade may serve as a model for future clinical research that is more rapid, innovative, and inclusive, according to a recent report published by Herbst et al in Clinical Cancer Research.

Background

The Lung-MAP...

Bladder Cancer
Immunotherapy

Disitamab Vedotin in Previously Treated Patients With Advanced HER2-Positive Urothelial Carcinoma

In a combined analysis of two Chinese phase II trials (RC48-C005 and RC48-C009) reported in the Journal of Clinical Oncology, Sheng et al found that the antibody-drug conjugate disitamab vedotin—an anti-HER2 antibody conjugated with monomethyl auristatin—produced promising results in patients with...

Lung Cancer

Adding Tiragolumab to Atezolizumab and Chemotherapy in Previously Untreated Extensive-Stage SCLC

As reported in the Journal of Clinical Oncology by Charles M. Rudin, MD, PhD, and colleagues, the phase III SKYSCRAPER-02 trial showed no progression-free or overall survival benefit with the addition of the T-cell immunoglobulin and ITM domain (TIGIT) inhibitor tiragolumab to atezolizumab and...

Survivorship

Predicting Primary Ovarian Insufficiency in Childhood Cancer Survivors

As reported in The Lancet Oncology, Im et al have developed risk-prediction models for primary ovarian insufficiency in long-term survivors of childhood cancer.

Study Details

In the study, models to predict age-specific risk of primary ovarian insufficiency were evaluated among 5-year survivors...

Lymphoma
Leukemia

FDA Grants Accelerated Approval to Pirtobrutinib for CLL/SLL

On December 1, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib (Jaypirca) for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a Bruton’s tyrosine...

Prostate Cancer
Issues in Oncology

Black Men With Advanced Prostate Cancer May Be Less Likely to Receive Treatment

Investigators have found that Black men diagnosed with more advanced stages of prostate cancer may be significantly less likely to be prescribed novel hormone therapy compared with men from other racial and ethnic groups, according to a recent study published by Martin et al in JAMA Network Open....

Colorectal Cancer
Survivorship
Supportive Care

Consuming Navy Beans May Improve Gut Health, Regulate Immune and Inflammatory Processes in Colorectal Cancer Survivors

Researchers have uncovered that the regular consumption of navy beans may help modulate markers linked to obesity and disease and improve the gut microbiome in colorectal cancer survivors, according to a novel study published by Zhang et al in eBioMedicine.

Background

Obesity, poor diet, and...

Breast Cancer
Issues in Oncology

Regular Screening Mammograms May Significantly Reduce Breast Cancer Mortality, Swedish Study Shows

Patients who regularly attend screening mammograms may have a reduced risk of breast cancer mortality, according to recent findings presented by Smith et al at the Radiological Society of North America (RSNA) 2023 Scientific Assembly and Annual Meeting (Abstract R1-SSBR10-4).

Background

Early...

Lung Cancer
Immunotherapy
Issues in Oncology

Toxicities Potentially Linked to Combination Immunotherapy for Mesothelioma

The combination of ipilimumab and nivolumab may result in a higher levels of toxicities in patients with unresectable pleural mesothelioma than was reported in the CheckMate 743 trial, according to a recent study published by McNamee et al in the Journal of Thoracic Oncology.

Background

Australia...

Colorectal Cancer

Colorectal Cancer: Incidence and Time to Recurrence

In a nationwide Danish cohort study reported in JAMA Oncology, Nors et al found the 5-year risk of recurrence after surgery for stage I to III colorectal cancer decreased over time and the time to recurrence was shorter with a more advanced disease stage.

Study Details

The study used the Danish...

Lung Cancer

Risk-Adapted Radioimmunotherapy for Locally Advanced PD-L1–Positive NSCLC

In the phase II SPRINT trial reported in the Journal of Clinical Oncology, Ohri et al found that a chemotherapy-sparing regimen of pembrolizumab with risk-adapted radiotherapy was associated with good outcomes in patients with stage III or unresectable stage II non–small cell lung cancer (NSCLC)...

Colorectal Cancer
Survivorship

Risk of Subsequent Colorectal Cancer After Abdominopelvic Radiotherapy Among Childhood Cancer Survivors

In a European study reported in the Journal of Clinical Oncology, Heymer et al found that the risk of subsequent colorectal cancer was elevated among childhood cancer survivors who had undergone abdominopelvic radiotherapy.

Study Details

The study used data from the PanCareSurFup Study—a...

Leukemia

Inotuzumab Ozogamicin–Based Induction in Older Patients With Philadelphia Chromosome–Negative B-Cell–Precursor ALL

In a German phase II trial (INITIAL-1) reported in the Journal of Clinical Oncology, Matthias Stelljes, MD, and colleagues found that inotuzumab ozogamicin–based induction therapy followed by age-adapted chemotherapy was associated with promising outcomes in newly diagnosed patients older than age...

Lung Cancer
Issues in Oncology

Novel AI Model May Predict Nonsmokers at High Risk for Lung Cancer

An artificial intelligence (AI) model may be capable of using routine chest x-ray images to identify nonsmokers who may be at high risk for lung cancer, according to new findings presented by Walia et al at the Radiological Society of North American (RSNA) 2023 Scientific Assembly and Annual...

Hepatobiliary Cancer

Trastuzumab Plus Gemcitabine/Cisplatin in Advanced HER2-Positive Biliary Tract Adenocarcinoma

In an Indian phase II trial reported in the Journal of Clinical Oncology, Ostwal et al found that trastuzumab plus gemcitabine/cisplatin was active in treatment-naive patients with advanced HER2-positive biliary tract adenocarcinoma.

Study Details

In the investigator-initiated multicenter trial,...

Breast Cancer

Incidence of Breast Cancer After False-Positive Mammography

In a Swedish study reported in JAMA Oncology, Mao et al found that women with a false-positive mammography result were more likely to be subsequently diagnosed with breast cancer compared to women with no false-positive result.

Study Details

The study involved data from 45,213 women who received...

Issues in Oncology
Immunotherapy

FDA Investigating Risk of T-Cell Malignancy Following BCMA- or CD19-Directed Autologous CAR T-Cell Immunotherapies

The U.S. Food and Drug Administration (FDA) has received reports of T-cell malignancies, including chimeric antigen receptor (CAR)-positive lymphoma, in patients who received treatment with B cell maturation antigen (BCMA)- or CD19-directed autologous CAR T-cell immunotherapies. Reports were...

Lymphoma

CNS Prophylaxis With High-Dose Methotrexate in High-Risk Aggressive B-Cell Lymphoma

In a retrospective study reported in the Journal of Clinical Oncology, Lewis et al found that prophylactic high-dose methotrexate did not appear to offer a clinically meaningful reduction in risk of central nervous system (CNS) disease progression in patients with high-risk aggressive B-cell...

Lung Cancer
Issues in Oncology

Durvalumab May Offer Survival Benefit in Patients With NSCLC and Borderline Performance Status

The immune checkpoint inhibitor durvalumab may be safe and effective at improving overall survival in patients who have advanced or metastatic non–small cell lung cancer (NSCLC) and borderline performance status, according to a recent study published by Shaverdashvili et al in eClinicalMedicine.  

...

Breast Cancer
Issues in Oncology

Urban Environmental Exposures and Incidence of Breast Cancer

Investigators have uncovered that North Carolina’s urban counties may have higher overall incidences of breast cancer than its rural counties, especially at early stages at diagnosis, according to a recent study published by Gearhart-Serna et al in Scientific Reports. These findings may serve as a...

Gastroesophageal Cancer

Adding Atezolizumab to Perioperative Chemotherapy in Resectable Esophagogastric Cancer

As reported in the Journal of Clinical Oncology by Lorenzen et al, the phase II portion of the German-Swiss phase II/III DANTE/IKF-s633 trial showed promising results with the addition of atezolizumab to perioperative chemotherapy in patients with resectable esophagogastric cancer.

Study Details

...

Prostate Cancer
Genomics/Genetics

Outcomes With Olaparib in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer in the PROfound Trial

In an analysis of the phase III PROfound trial reported in the Journal of Clinical Oncology, Joaquin Mateo, MD, PhD, and colleagues found that olaparib improved outcomes vs abiraterone or enzalutamide among the subgroup of patients with metastatic castration-resistant prostate cancer who had...

Gynecologic Cancers

Novel Uterine Cancer Detection Method for Women With Abnormal Uterine Bleeding

In a UK single-institution study (EPI-SURE) reported in The Lancet Oncology, Evans et al found that the novel WID-qEC DNA methylation test outperformed ultrasonography in detecting uterine cancer in women with abnormal uterine bleeding. 

Study Details

The prospective observational study invited...

Colorectal Cancer
Issues in Oncology

Lack of Basic Care in Patients With Colorectal Cancer in Sub-Saharan Africa

A high proportion of patients with colorectal cancer in Sub-Saharan Africa may receive no treatment or inadequate treatment, regardless of the disease’s curability, according to a recent study published by Hämmerl et al in JNCCN–Journal of the National Comprehensive Cancer Network. The new findings ...

FDA Approves Nirogacestat for Desmoid Tumors

On November 27, the U.S. Food and Drug Administration (FDA) approved the selective gamma secretase inhibitor nirogacestat (Ogsiveo) for adult patients with progressing desmoid tumors who require systemic treatment. This is the first approved treatment for desmoid tumors.

DeFi Trial

Efficacy was...

Leukemia

Blinatumomab as an Alternative to First-Line Intensive Chemotherapy in Pediatric B-Cell ALL

In a retrospective study reported in the Journal of Clinical Oncology, Hodder et al found that blinatumomab was effective as a toxicity-sparing alternative to first-line intensive chemotherapy in children and young persons with B-cell acute lymphoblastic leukemia (ALL) who were...

Breast Cancer

Axillary Soft-Tissue Involvement in Lymph Node–Positive Breast Cancer

In a single-institution retrospective analysis reported in the Journal of Clinical Oncology, Naoum et al found that pathologic exploration of axillary soft tissue in patients with lymph node–positive breast cancer is a critical element in predicting disease outcome and in determining axillary...

Gynecologic Cancers

Early-Stage Cervical Cancer: Defining Follow-up After Fertility-Sparing Surgery

In a Dutch retrospective cohort study reported in The Lancet Oncology, Schuurman et al identified follow-up strategies based on cytology and human papillomavirus (HPV) testing after fertility-sparing surgery for early-stage cervical cancer.

Study Details

The nationwide population-based study used ...

Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer: Efficacy of Anti-PSMA Antibody With Alpha Emitter

In a phase I study reported in the Journal of Clinical Oncology, Scott T. Tagawa, MD, MS, FASCO, FACP, and colleagues determined the recommended phase II dose and described preliminary activity of actinium-225–J591—an anti–prostate-specific membrane antigen (PSMA) monoclonal antibody (J591)...

Lung Cancer

Adding Pembrolizumab to Chemotherapy for Previously Untreated Advanced Pleural Mesothelioma

As reported in The Lancet by Chu et al, a phase III trial conducted in Canada, Italy, and France showed that the addition of pembrolizumab to chemotherapy improved survival in previously untreated patients with advanced pleural mesothelioma.

Study Details

In the multicenter open-label trial, 440...

ASCO Applauds Appointment of W. Kimryn Rathmell, MD, PhD, as Next NCI Director

On November 17, President Joe Biden announced the appointment of W. Kimryn Rathmell, MD, PhD, Chair of Medicine at Vanderbilt University Medical Center and Physician-in-Chief for Vanderbilt University Adult Hospital and Clinics, as his choice for Director of the National Cancer Institute (NCI).

...

Skin Cancer
Immunotherapy

Major Pathologic Response to Neoadjuvant Pembrolizumab in Advanced Melanoma Trial Exceeds 50%

In exploratory analyses of results from the SWOG S1801 trial in patients with stage III to IV resectable melanoma, researchers saw a major pathologic response in more than half of surgical specimens taken from patients who had been treated with neoadjuvant pembrolizumab.

These and other results of ...

Colorectal Cancer

Prevalence of Unsatisfactory Samples From FIT Tests for Colorectal Cancer Screening

A retrospective cohort study by Liu et al published in Cancer Epidemiology, Biomarkers & Prevention investigated the prevalence and reasons for an unsatisfactory fecal immunochemical test (FIT). Researchers found that over 10% of the tests used for routine colorectal cancer screening contained...

Breast Cancer

Early Breast Cancer: Effect of Radiotherapy to Regional Nodes

As reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), an individual patient meta-analysis has shown that more recent—but not older—trials of regional lymph node radiotherapy vs no radiotherapy in patients with early breast cancer showed benefits of...

Breast Cancer

Overall Survival With CTC Count–Driven Treatment in Advanced Breast Cancer

As reported in the Journal of Clinical Oncology by François-Clément Bidard, MD, PhD, and colleagues, the French phase III STIC CTC trial showed a nonsignificant overall survival benefit with a circulating tumor cell (CTC) count–driven approach to therapy vs physician’s choice in the first-line...

Colorectal Cancer

Addition of Adjuvant HIPEC to Standard Chemotherapy in Locally Advanced Colon Cancer

As reported in the Journal of Clinical Oncology by Zwanenburg et al, 5-year findings from the Dutch COLOPEC trial indicated that the addition of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) to systemic chemotherapy did not improve overall survival vs chemotherapy alone in patients...

Prostate Cancer

FDA Approves Enzalutamide for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence

On November 16, the U.S. Food and Drug Administration (FDA) approved the androgen receptor inhibitor enzalutamide (Xtandi) for patients with nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.

EMBARK Trial

Efficacy was evaluated in EMBARK...

Solid Tumors
Issues in Oncology

Updated Findings on Increased Cancer Occurrence in Sweden After 1986 Chernobyl Accident

Researchers have uncovered an increased incidence of certain types of cancer in Sweden following the Chernobyl nuclear power plant accident, according to a novel study published by Tondel et al in Environmental Epidemiology.

Study Methods and Results

The Chernobyl accident in 1986 led to the...

Breast Cancer

Partial-Breast Irradiation in Patients With Early-Stage Invasive Breast Cancer or DCIS

The American Society for Radiation Oncology (ASTRO) issued recommendations for patient-centered strategies for performing partial-breast irradiation in patients with early-stage invasive breast cancer or ductal carcinoma in situ (DCIS). The new clinical guidelines were published by Shaitelman et al ...

Breast Cancer

FDA Approves Capivasertib With Fulvestrant for Breast Cancer

On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations, as detected by an...

Lung Cancer
Issues in Oncology

Study Questions Role of Extended Pleurectomy Decortication in Patients With Mesothelioma

Extended pleurectomy decortication combined with chemotherapy was associated with worse survival outcomes, a higher incidence of serious adverse events, and a diminished quality of life in patients with resectable mesothelioma compared with platinum and pemetrexed chemotherapy alone, according to...

Lung Cancer
Issues in Oncology

Modified Classification of Pulmonary Adenocarcinomas May Be More Accurate Than WHO Classification System

A modified adenocarcinoma classification approach may enhance reproducibility and may be an improvement on the existing World Health Organization (WHO) classification system, according to findings presented by Thunnissen et al at the International Association for the Study of Lung Cancer (IASLC)...

Lung Cancer
Issues in Oncology

Taiwanese Program Shows Potential for Detecting Early-Stage Lung Cancer

Researchers have found that the Taiwan National Lung Cancer Early Detection Program successfully detected 85% of stage 0 and stage I lung cancer cases. The findings by Yang et al were presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung...

Lung Cancer
Issues in Oncology

AEGEAN Trial: Addition of Perioperative Durvalumab to Neoadjuvant Chemotherapy in Resectable NSCLC

The addition of perioperative durvalumab to neoadjuvant chemotherapy may be associated with a tolerable surgical safety profile and may not adversely impact surgery in patients with resectable non–small cell lung cancer (NSCLC), according to new findings presented by Mitsudomi et al at the...

Lung Cancer
Immunotherapy

Immunotherapy Combination vs Standard Chemotherapy for Metastatic NSCLC

Researchers have discovered that therapy with first-line nivolumab in combination with ipilimumab may improve the 6-year survival and quality of life of patients with metastatic non–small cell lung cancer (NSCLC) compared with standard chemotherapy, according to findings presented by Peters et al...

Lung Cancer

Is Adagrasib Active in KRAS G12C–Mutated NSCLC?

The oral KRAS G12C inhibitor adagrasib may offer durable clinical activity, with a median overall survival of 14.1 months and a 2-year survival rate of about 33%, in patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to findings presented by Gadgeel et al at the...

Lung Cancer
Issues in Oncology

Impact of Stigmatization on Patients With Lung Cancer

The stigma that patients face when diagnosed with lung cancer may be associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to findings presented by Harrison et al at the International Association for...

Lung Cancer

Extensive-Stage Small Cell Lung Cancer: Triplet Combination vs Chemotherapy Alone

The combination of benmelstobart, anlotinib, and chemotherapy may be effective at improving median progression-free survival and overall survival in patients with extensive-stage small cell lung cancer compared with placebo and chemotherapy, according to findings presented by Cheng et al at the...

Lung Cancer
Supportive Care

Comparing Radiation Therapies for NSCLC

Intensity-modulated radiation therapy may be the preferred treatment option for patients with locally advanced non–small cell lung cancer (NSCLC), according to findings presented by Chun et al at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer ...

Lung Cancer
Issues in Oncology

Accuracy of IASLC's 2009 Database for Pleural Mesothelioma Staging

Researchers have validated the accuracy of the International Association for the Study of Lung Cancer’s (IASLC) 2009 pleural mesothelioma database, with these findings presented by Wolf et al at the IASLC 2023 World Conference on Lung Cancer (Abstract MA17.04).

Background

Pleural mesothelioma...

Lung Cancer
Issues in Oncology

LungCAN Advocacy Program Nets 25% Increase in LCRP Funding

The Lung Cancer Action Network (LungCAN) advocacy program may have helped increase funding for the U.S. Department of Defense Congressionally Directed Medical Research Program/Lung Cancer Research Program (LCRP) by 25%, according to recent findings presented by Donaldson et al at the International...

Lung Cancer
Issues in Oncology

Reproductive Factors May Be Associated With Higher Risk of Lung Cancer in Women

Investigators have discovered that women with certain reproductive factors may have an elevated risk of developing lung cancer, according to recent findings presented by Zhang et al at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (Abstract...

Lung Cancer
Genomics/Genetics
Immunotherapy

Do Checkpoint Inhibitors Show Benefit in EGFR-Mutated NSCLC After Progression?

In patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR mutations, the role of immune checkpoint inhibitors following disease progression with tyrosine kinase inhibitors has been unclear. Several studies reported at the International Association for the Study of Lung Cancer 2023 ...

Lung Cancer

NSCLC: Osimertinib Plus Chemo vs Osimertinib Alone

Osimertinib plus chemotherapy may have demonstrated a statistically significant and clinically meaningful progression-free survival benefit in patients with advanced non–small cell lung cancer (NSCLC) compared with osimertinib alone, according to new findings presented by Jänne et al at the...

Lung Cancer
Issues in Oncology

EGFR Tyrosine Kinase Inhibitors vs Durvalumab in EGFR-Mutated NSCLC: Impact on Survival

Researchers have discovered that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors may improve survival outcomes after treatment with chemoradiation in patients with stage III EGFR-mutated non–small cell lung cancer (NSCLC) compared to the PD-L1 inhibitor durvalumab, according to...

Multiple Myeloma
Immunotherapy

Ciltacabtagene Autoleucel vs Standard Care in Patients With Lenalidomide-Refractory Multiple Myeloma

In the phase III CARTITUDE-4 trial reported in The New England Journal of Medicine, San-Miguel et al found that receipt of ciltacabtagene autoleucel following bridging therapy significantly improved progression-free survival vs standard care in patients with lenalidomide-refractory multiple...

Lung Cancer

FDA Approves Next-Generation Tyrosine Kinase Inhibitor Repotrectinib for ROS1-Positive NSCLC

On November 15, 2023, the U.S. Food and Drug Administration (FDA) approved the next-generation tyrosine kinase inhibitor repotrectinib (Augtyro) for the treatment of locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC). According to the American Lung Association, the ROS1 ...

Kidney Cancer

Modified vs Standard Ipilimumab Plus Nivolumab in Advanced Renal Cell Carcinoma

In a UK phase II trial (PRISM) reported in the Journal of Clinical Oncology, Vasudev and colleagues found that ipilimumab given every 12 weeks vs every 3 weeks in combination with nivolumab resulted in a significantly reduced rate of treatment-related grade ≥ 3 adverse events in treatment-naive...

Leukemia

Ibrutinib/Venetoclax vs Chlorambucil/Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia: GLOW Trial 4-Year Follow-up

As reported in The Lancet Oncology by Niemann et al, the 4-year follow-up of the phase III GLOW trial has shown a continued progression-free survival benefit with fixed-duration ibrutinib/venetoclax vs chlorambucil/obinutuzumab in the first-line treatment of chronic lymphocytic leukemia in patients ...

Skin Cancer
Issues in Oncology

Occupational Exposure to Solar UV Radiation and Nonmelanoma Skin Cancer

Individuals who experience occupational exposure to solar ultraviolet (UV) radiation may have a high rate of nonmelanoma skin cancer incidence and mortality, according to a recent study published by Pega et al in Environment International. These findings highlighted the large and increasing burden...

Solid Tumors
Issues in Oncology

Number of Cancer Treatments Performed During Early COVID-19 Pandemic

Investigators have uncovered that fewer surgical, chemotherapy, and radiation treatments may have been performed in patients with cancer during the first months of the COVID-19 pandemic, according to a recent study published by Nogueira et al in JAMA Oncology. The new findings may be attributable...

Colorectal Cancer

Racial Disparities in Guideline-Concordant Care in Early-Onset Colorectal Cancer in the United States

In a study reported in the Journal of Clinical Oncology, Nogueira et al found that among U.S. Black and White patients with early-onset colorectal cancer, Black patients were more likely to receive poorer and less timely care.

As stated by the investigators: “Young individuals racialized as Black...

Hepatobiliary Cancer

AI-Based Pathology for Assessing Sensitivity to Atezolizumab/Bevacizumab in HCC

As reported in The Lancet Oncology, Zeng et al developed an artificial intelligence (AI)-based pathology method that distinguished between better and poorer response to treatment with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma (HCC).

As stated by the investigators:...

Leukemia
Supportive Care

Vitamin C and D Supplements for Patients With AML Undergoing Intensive Chemotherapy

Patients with acute myeloid leukemia (AML) who received vitamin C and D supplements during intensive chemotherapy had lower rates of complications such as infections, bleeding, and inflammation compared with patients who did not receive the supplements, according to a recent study published by...

Leukemia
Genomics/Genetics

Novel Assay May Help Detect and Treat Patients With AML

A novel assay may be effective at detecting a unique molecular marker in patients with acute myeloid leukemia (AML), according to a recent study published by Young et al in The Journal of Molecular Diagnostics. The new findings may revolutionize the way AML is detected and treated.

Background

AML ...

Gynecologic Cancers

Ofranergene Obadenovec With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer

In a phase III trial (OVAL Study/GOG 3018) reported in the Journal of Clinical Oncology, Arend et al found that the addition of ofranergene obadenovec to paclitaxel did not improve survival outcomes in patients with platinum-resistant ovarian cancer. Ofranergene obadenovec is a gene-based targeted...

Prostate Cancer
Genomics/Genetics

Researchers Identify Novel Genetic Variants Predictive of Prostate Cancer Risk and Severity

Researchers have compiled a comprehensive list of genetic variants that may be associated with the risk of developing prostate cancer, according to a recent study published by Wang et al in Nature Genetics. The new findings included major increases in representation among patients from racial and...

Colorectal Cancer

Long-Term Organ Preservation With Total Neoadjuvant Therapy in Rectal Adenocarcinoma

In a 5-year follow-up of the phase II OPRA trial reported in the Journal of Clinical Oncology, Verheij et al found that many patients receiving total neoadjuvant therapy for rectal adenocarcinoma remained free of the need for total mesorectal excision.

Study Details

In the U.S. multicenter...

Prostate Cancer
Issues in Oncology

Comparing the Accuracy of Initial Staging Methods in Prostate Cancer

Bone scans may overstage prostate cancer at initial staging compared with prostate-specific membrane antigen (PSMA) positron-emission tomography (PET), according to a recent study published by Hope et al in The Journal of Nuclear Medicine.

Background

PSMA PET is known to be more accurate than...

Global Cancer Care

Advancing Clinical Research on Ovarian Cancer and Overcoming Gender Inequity in Low- and Middle-Income Countries

The management of ovarian cancer remains challenging within health-care systems worldwide. Recently, clinical and translational research on ovarian cancer has led to promising advances that have improved the survival outcomes of women diagnosed with this aggressive gynecologic cancer. These...

Hematologic Malignancies
Issues in Oncology

Exposure to CT Radiation and Risk of Blood Cancers in Young Patients

Investigators may have uncovered an association between exposure to computed tomography (CT) radiation in young patients and an increased risk of hematologic malignancies, according to a recent study published by Bosch de Basea Gomez et al in Nature Medicine. These recent findings highlighted the...

Colorectal Cancer
Issues in Oncology

Cancer Care Disparities Among Patients With Early-Onset Colorectal Cancer

Investigators have found that Black patients with early-onset colorectal cancer in the United States may receive worse and less timely, guideline-concordant care than White patients, according to a recent study published by Nogueira et al in the Journal of Clinical Oncology.

Background

...

Lung Cancer

Osimertinib With or Without Chemotherapy in EGFR-Mutant Advanced NSCLC

As reported in The New England Journal of Medicine by Planchard et al, the phase III FLAURA2 trial has shown superior progression-free survival with osimertinib plus platinum-based chemotherapy vs osimertinib alone in the first-line treatment of EGFR-mutant advanced non–small cell lung cancer...

Lymphoma

Effect of Bendamustine Prior to Apheresis on Outcomes in Large B-Cell Lymphoma Treated With CAR T-Cell Therapy

In a retrospective study reported in the Journal of Clinical Oncology, Iacoboni et al found that preapheresis bendamustine exposure was associated with poorer outcomes among patients with relapsed or refractory large B-cell lymphoma receiving CD19-targeted chimeric antigen receptor (CAR) T-cell...

Kidney Cancer

Belzutifan Improves Outcomes for Pretreated Patients With Clear Cell Renal Cell Carcinoma Compared to Everolimus

The hypoxia-inducible factor (HIF)-2α inhibitor belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma in patients previously treated with immune checkpoint inhibitors and antiangiogenic therapies compared with everolimus. The phase III LITESPARK-005 trial, led...

Advertisement

Advertisement



Advertisement